KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Kyverna Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$5.83+0.16 (+2.82%)

Close on Oct 19, 2026

Market cap: $355.03M
P/E (TTM): –
Dividend yield: –

Kyverna Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Depreciation & Amortization	1.80	2.13	1.71
Stock-Based Compensation	10	8.36	2.22
Change in Accounts Payable	0.54	0.74	4.08
Operating Cash Flow	-154	-114	-52
Capital Expenditures	-0.01	-2.21	-0.62
Sale of Property, Plant & Equipment	0.07	0	–
Purchase of Investments	-365	-490	-55
Sale & Maturity of Investments	406	331	47
Investing Cash Flow	40	-161	-8.79
Stock Issued	17	0	–
Financing Cash Flow	141	337	58
Net Change in Cash	27	62	-3.08
Free Cash Flow	-154	-116	-53
Income Taxes Paid	0	0	–
Interest Paid	0.42	0.14	0.19

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -64.7%

Financial strength

Current ratio: 9.06
Debt to equity: 0.15
Debt to assets: 11.3%
Cash to current liabilities: 139.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.14
Dividend yield: –